Do you want to read an article? Please log in or register.
Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
Ther Adv Respir Dis.
Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P, Debonnett L, Hamed K
doi: 10.1177/
CoughPulmonary Fibrosis
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Lancet Respir Med.
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
J Cyst Fibros.
Kaplan S, Lee A, Caine N, Charman SC, Bilton D
doi: 10.1016/j.jcf.2020.08.001.
RECOMMENDED
Pulmonary Fibrosis
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kaplan S, Lee A, Caine N, Charman SC, Bilton D
doi: 10.1016/j.jcf.2020.08.001
RECOMMENDED
Bronchi
Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Martínez-García MÁ, Oscullo G, Barreiro E, Cuenca S, Cervera A, Padilla-Galo A, de la Rosa D, Navarro A, Giron R, Carbonero F, Castro Otero M, Casas F
doi: 10.3390/jcm9072317.
RECOMMENDED
Pulmonary Fibrosis
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F
doi: 10.1016/S2213-2600(20)30517-8
RECOMMENDED
CoughPulmonary Fibrosis
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA
doi: 10.1016/S2213-2600(21)00069-2
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
RECOMMENDED
Further Publications
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, VX14-661-110 study group.
doi: 10.1016/S2213-2600(20)30510-5